Biomedical subjects
Publications and source records attributed to T J Wiktor.
The HEP and ts2 strains of rabies virus inoculated intracerebrally into adult mice normally cause clinically inapparent infection. In the experiments described, this is converted into a lethal infection by immunosuppression with cyclophosphamide, which also prevented induction of immunity with vaccine. Lethal infection of HEP-inoculated mice was also observed in mice treated with antihymocytic serum, and in athymic (BALB/c-nu) nude mice.
Introductory remarks on the advantages of antirabies vaccines obtained from human diploid cell cultures in comparison with brain tissue vaccine and duck embryo vaccine. The characteristics of these new types of vaccine are: (i) high antigenicity, (ii) rapid development of antibodies, (iii) absence of adverse reactions even when the booster inoculation was given two years later. The disadvantage is the high cost of production to obtain a highly purified product.
880 individuals, 120 of which were exposed to rabid animals, were immunized pre- or post-exposure with 2 different BPL-inactivated and concentrated rabies vaccines prepared in HDC strains WI-38 and MRC-5. The vaccines were well tolerated and no major side effects were observed after primary immunization with 3-10 doses or 1 booster vaccination. The dynamics of neutralizing, antibody formation and persistence of antibodies in 4 different groups of vaccinees are described. The groups were vaccinated pre-exposure (I) on days 0, 28 and 56; (II) on days 0, 7 and 14; (III) on days 0, 3, 7 and 21; and (IV) post-exposure on days 0, 3, 7, 14, 30 and 90. High antibody levels--persisting for at least 30 months--were obtained in all patients. The CFT, using a concentrated and purified virion antigen, was highly specific for rabies virus antibody demonstration. Since in some 50 patients under severe risk, after having been bitten and/or scratched by proven rabid animals, not a single breakthough of immunity was observed during an observation time between 1/2 and 3 years, the protective effect of the HDCS-rabies vaccines seems to be excellent. With regard to their high immunogenicity and extremely low reactogenicity, the new HDCS-vaccines can be recommended for prophylactic and post-exposure immunization of man without any reserve. Data on simultaneous application of homologous anti-rabies gammaglobulin from man (20 I.E./kg body-weight) and HDCS-vaccines are also presented and discussed.